Huron Consulting Group Inc. Q4 FY2024 earnings call

Management Statement and Operational Highlights

• Growth and Margins: The fourth quarter of 2024 saw record RBR, with 9% RBR growth in 2024 over 2023. Adjusted EBITDA margins expanded for the fourth consecutive year.
• Segment Specifics: Healthcare benefited from strong demand in performance improvement, revenue cycle, and digital offerings. Education was boosted by the GG+A acquisition and demand for digital/strategy and operations. Commercial was driven by the AXIA acquisition and financial advisory growth.
• Market Commentary: Healthcare faces margin pressures and regulatory changes; Education deals with reduced research funding; Commercial faces macroeconomic/geopolitical uncertainty.
• Culture and Awards: Huron has a strong collaborative culture, named Best Place to Work by Glassdoor, with growth in leadership and employee base.

Segment Performance

• Healthcare Segment: In the fourth quarter of 2024, RBR was $202.3 million, up 17.6% from the prior year quarter, contributing 52% of total company RBR. Full-year 2024 RBR was $756.3 million, up 12.2% from 2023, driven by strong demand for performance improvement, revenue cycle, managed services, and digital offerings.
• Education Segment: Fourth quarter 2024 RBR was $118.8 million, up 14.5% from the prior year quarter, contributing 31% of total company RBR. Full-year 2024 RBR was $474.2 million, up 10.4% from 2023, boosted by the acquisition of GG+A and demand for digital and strategy and operations offerings.
• Commercial Segment: Fourth quarter 2024 RBR was $67.3 million, up 6.1% from the prior year quarter, contributing 17% of total company RBR. Full-year 2024 RBR was $255.6 million, down 1.1% from 2023, affected by reduced demand for strategy and innovation offerings but offset by growth in financial advisory.

Guidance

• 2025 RBR: Expected to be $1.58 billion to $1.66 billion, representing a 9% year-over-year growth midpoint.
• Adjusted EBITDA Margin: Projected to be in the range of 14% to 14.5% of RBR, a 75 basis point improvement from 2024.
• Adjusted Diluted EPS: Expected to be $6.80 to $7.60, an 11% increase from 2024.
• Cash Flows: Cash from operations expected to be $195 million to $235 million, with free cash flow in the range of $160 million to $190 million.

Risks

• Healthcare: Declining provider margins, regulatory changes (e.g., clinical reimbursement, 340B drug reimbursement, tariffs).
• Education: Reduced federal research funding, indirect cost reimbursement rate caps, immigration policy changes, tax on endowments.
• Commercial: Macroeconomic and geopolitical uncertainty, evolving regulatory environment.

Question and Answer

• Q: Andrew Nicholas on regulatory backdrop and pipeline impact A: Mark Hussey and John Kelly discuss pipeline robustness, client needs, and investments in GG+A and AXIA to address client challenges.
• Q: Tyler Barishaw on education research funding impact and utilization expectations A: Mark Hussey explains reduced research funding impact on education clients, and expects improved utilization in 2025.
• Q: Bill Sutherland on commercial digital growth and healthcare guidance A: John Kelly discusses commercial digital pipeline and growth expectations, while Mark Hussey provides insights on healthcare mid-single-digit growth guidance.
• Q: Kevin Steinke on commercial digital pipeline and healthcare service broadening A: John Kelly talks about commercial digital backlog coverage and confidence, while Mark Hussey outlines plans to broaden healthcare services in areas like financial advisory and managed services